Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Completed · Phase 3

Conditions studied: Gaucher Disease, Type 1

In brief

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.

Key facts

Study ID

NCT00553631

Run by

Shire

People needed

34

Starts

2008-01-29

Expected to finish

2009-05-05

Last updated by the study team

2021-06-08

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Includes:
• The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher disease
• The patient is at least 2 years of age.
• The patient has not received treatment for Gaucher disease (investigational products, miglustat, or imiglucerase) within 12 months prior to study entry, as documented in the patient's medical history.
• Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
• The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
• The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.

You may not qualify if…

• Includes:
• The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease.
• The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted.
• The patient is known to be positive for human immunodeficiency virus (HIV).
• The patient is known to be positive for hepatitis B and/or C.
• The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.
• The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.).
• The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator.

Where it is running

• Duke Children's Hospital & Health Center — Durham, North Carolina, United States
• Your Health S.A. — Buenos Aires, Argentina
• Malabar Institute of Medical Sciences Ltd. — Calicut, Kerala, India
• All India Institute of Medical Sciences — New Delhi, India
• KEM Hospital Research Centre — Pune, India
• Shaare Zedek Medical Center — Jerusalem, Israel
• Sociedad Espanola de Socorros Mutuos — Asunción, Paraguay
• National Research Center for Haematology — Moscow, Russia
• Hospital Universitario Miguel Servet — Zaragoza, Spain
• La Rabta Hospital — Tunis, Tunisia
• The Royal Free Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.